Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 3—March 2019
Dispatch

In Vivo Selection of a Unique Tandem Repeat Mediated Azole Resistance Mechanism (TR120) in Aspergillus fumigatus cyp51A, Denmark

Figures
Tables
Article Metrics
24
citations of this article
EID Journal Metrics on Scopus
Rasmus K. HareComments to Author , Jan B. Gertsen, Karen M.T. Astvad, Kristine B. Degn, Anders Løkke, Marc Stegger, Paal S. Andersen, Lise Kristensen, and Maiken C. ArendrupComments to Author 
Author affiliations: Statens Serum Institut, Copenhagen, Denmark (R.K. Hare, K.M.T. Astvad, M. Stegger, P.S. Andersen, M.C. Arendrup); Åarhus University Hospital, Åarhus, Denmark (J.B. Gertsen, K.B. Degn, A. Løkke, L. Kristensen); Rigshospitalet, Copenhagen (M.C. Arendrup); University of Copenhagen, Copenhagen (M.C. Arendrup)

Cite This Article

Abstract

We report a fatal aspergillosis case in which STRAf typing and whole-genome sequencing substantiated in vivo emergence of an azole-resistant Aspergillus fumigatus with a 120-bp tandem repeat in the promoter region of cyp51A. This event, previously restricted to the environment, challenges current understanding of azole resistance development in A. fumigatus.

Azole antifungal drug resistance in Aspergillus fumigatus is a concern for patients with aspergillosis because of increased risk for disease and death (1). Two routes of acquiring azole resistance have been identified: 1) in vivo, as a consequence of long-term azole treatment; and 2) ex vivo, in the environment, resulting from the use of azole fungicides in crop protection. The underlying mechanisms are primarily linked to structural changes or upregulation of the azole target lanosterol 14 α-demethylase encoded by cyp51A (1). Most environmentally induced resistance mechanisms involve tandem repeats (TRs) in the promoter region of cyp51A coupled with nonsynonymous mutations, TR34/L98H and TR46/Y121F/T289A (1). However, in vivo resistance development has primarily been associated with nonsynonymous mutations in cyp51A-inducing amino acid substitutions of hot spots (e.g., G54, G138, M220, and G448) or non–cyp51A-mediated mechanisms, but not a tandem repeat (1). We describe a clinical case of infection with azole-resistant A. fumigatus that acquired a 120-bp tandem repeat (TR120) resistance mechanism during long-term azole treatment. The finding was substantiated by whole-genome sequencing (WGS).

The Study

Figure 1

Thumbnail of Sequential thoracic computed tomography scan images illustrating the gradual progression from pleural thickening to cavity formation and development of an aspergilloma in a patient with Aspergillus fumigatus infection, Denmark, 2013. A) 2011, B) 2012, C) 2014, D) 2016.

Figure 1. Sequential thoracic computed tomography scan images illustrating the gradual progression from pleural thickening to cavity formation and development of an aspergilloma in a patient with Aspergillus fumigatus infection, Denmark, 2013. A)...

In 2013, a 69-year-old man who was a former smoker with chronic obstructive pulmonary disease (COPD) and severe airflow obstruction sought care at the University Hospital in Århus, Denmark, because of gradually worsening dyspnea, cough, and expectoration. Previously, in 2011, imaging (Figure 1, panel A) and 2 thoracoscopies had been conducted because of suspicion of malignant mesothelioma. Further histopathologic examination and cultures revealed inflammation but no malignancy or mold infection. Subsequently, in 2012, a fistula between pleura and skin led to a persistent air-containing pleural cavity in the right side (Figure 1, panel B). In 2014, a fungus ball in the pleural cavity was found (Figure 1, panel C). Aspergillus IgG titer was 1:25,600 (reference range <1:200), and azole-susceptible A. fumigatus was cultured from sputum (P-1, May 2014). Voriconazole (200 mg 2×/d) was given, alternating with posaconazole (300 mg/d) for 2 years until clinical failure, and 2 azole-resistant A. fumigatus isolates were cultured from a new sputum sample (P-2 and P-3, June 2016). Despite amphotericin B inhalations followed by liposomal amphotericin B (3 mg/kg 1×/d), the patient died because of severe hemoptysis 1 year later in 2017.

Three A. fumigatus patient isolates (P-1, P-2, and P-3) were available for confirmatory species verification, reference susceptibility testing defined by the European Committee on Antimicrobial Susceptibility Testing using protocol for molds (E.Def 9.3), cyp51A Sanger sequencing (using wild-type reference sequence AF338659), and genotyping using the short tandem-repeat Aspergillus fumigatus (STRAf) assay (2,3) (Table). We included 4 A. fumigatus isolates representing relevant cyp51A profiles as control strains (SSI-3614 [wild-type], SSI-7828 [TR34/L98H], SSI-5717 [TR46/Y121F/T289A], and SSI-5197 [F46Y/M172V/E427K]). We detected 3 common Cyp51A variants (F46Y, M172V, and E427K) in the susceptible patient isolate P-1 (GenBank accession no. MG972984). Pan-azole resistance was observed for P-2 and P-3, and both shared cyp51A profiles with P-1 but also harbored a TR120 mechanism (GenBank accession no. MG972983) in the promoter region (Table). All patient isolates had identical STRAf genotypes suggesting that they were isogenic (Table ) (4). Furthermore, the STRAf profile was unique among A. fumigatus isolates genotyped in Denmark (Appendix Figure).

Figure 2

Thumbnail of Unrooted phylogenetic tree based on whole-genome sequencing of 2 patient isolates (P-1 and P-3) and 5 reference strains to highlight relatedness between Aspergillus fumigatus isolates, Denmark, 2018. We inferred relatedness by using FastTree version 2.1 (7) based on a 77.69% core genome. Whole-genome sequencing identified 41 single-nucleotide polymorphism (SNP) differences between P-1 and P-3. We observed subtle differences (&lt;5,000 SNPs) between unrelated patient isolate SSI-5197

Figure 2. Unrooted phylogenetic tree based on whole-genome sequencing of 2 patient isolates (P-1 and P-3) and 5 reference strains to highlight relatedness between Aspergillus fumigatus isolates, Denmark, 2018. We inferred relatedness by...

We performed WGS for P-1, P-3, and all control strains to investigate relatedness and other potential mechanisms conferring azole resistance. We subjected total DNA (≈10 ng/µL) to WGS (NextSeq 550; Illumina, https://www.illumina.com) by using Nextera DNA library preparation kit (Illumina) and following the manufacturer’s instructions. We used NASP (5) to detect single-nucleotide polymorphisms (SNPs) after removal of duplicated regions in the A. fumigatus strain Af293 chromosomes (http://www.aspergillusgenome.org, genome version s03-m05-r09) using NUCmer (6). We inferred relatedness by using FastTree version 2.1.5 (7) and a 77.69% core genome (Table; Figure 2). To increase resolution, we conducted a subanalysis for P-1 and P-3 (core genome 79.71%), which identified 41 SNP differences; 6 of the SNPs were nonsynonymous in genes with no previous reported association to azole resistance (Appendix Table 1), and 35 were either synonymous or in noncoding regions (Appendix Table 2).

Conclusions

WGS revealed 41 SNP differences between the susceptible and the resistant patient A. fumigatus isolates that evolved during 2 years, similar to a previously described case of in-host microevolution of A. fumigatus (4). This finding substantiated an isogenic relationship between P-1 and P-3 and demonstrated that the TR120 resistance mechanism emerged from P-1, probably during long-term azole therapy. Furthermore, WGS results supported the conclusion that the TR120 was the sole mechanism of azole resistance in the azole-resistant patient isolates.

To our knowledge, the TR120 is a novel azole-resistance mechanism in A. fumigatus, and the in vivo selection of a tandem repeat in the promoter of cyp51A is unique. The de novo acquisition of a TR has not previously been shown in vitro or in the environment (i.e., no isolates with L98H or Y121F+T289A combined with wild-type promoters have been reported). However, triplication of an existing TR34 on tebuconazole exposure was selected in vitro, and a novel variant, TR463, found in clinical and environmental samples, has been derived from sexual mating between TR46 parents (8,9).

Azole resistance involving TRs in the promoter region has been associated exclusively with environmental fungicide selection pressure in A. fumigatus and other plant pathogens. Furthermore, although asexual propagation of A. fumigatus with TR34/L98H or TR46/Y121F/T289A resistance mechanisms is widespread in the environment, the extent of de novo selection of TR34/L98H and TR46/Y121F/T289A is unclear (10). One hypothesis describes both environmental resistance mechanisms as being derived from single events of sexual reproduction (in environmental habitats) combining the TR with a cyp51A mutant. In addition, sexual reproduction might have led to a high genetic diversity among environmental azole-resistant A. fumigatus, which otherwise might have indicated multiple origins (10). Our finding might challenge the perception that TR azole-resistance mechanisms are exclusive to the environment and might warrant the question of whether TR34/L98H and TR46/Y121F/T289A derive from single events.

Hypothetically, the patient might initially have inhaled isogenic isolates with and without TR120, the resistant one being undetected. However, a patient being co-infected de novo by a susceptible and an isogenic resistant strain has not been previously reported and is considered highly unlikely.

Long-term and subtherapeutic antifungal treatment might facilitate selection of resistance (11). Therapeutic drug monitoring was performed once in this patient but without information if the sample was taken according to guidelines as a trough level (lowest level after dosage). Thus, despite a concentration of 4.3 mg/L (within the recommended trough range), potential subtherapeutic levels during the 200 mg 2×/d dosing scheme cannot be ruled out. The F46Y/M172V/E427K substitutions in Cyp51A, found in both susceptible and resistant isolates, have been suggested to play no role or only a minor role in reduced azole susceptibilities (12,13). TRs in the promoter region of cyp51A have previously been linked to increased cyp51A gene expression and MICs because of duplicated srbA transcription factor binding motifs (SRE1 and SRE2) leading to increased expression of cyp51A (14,15). Taken together, our data suggest that TR120 alone is an important driver of pan-azole resistance at a level comparable to that known to be mediated by the TR34/L98H mechanism.

Our WGS results might obviate the desire for in vitro experiments testing the TR120 mechanism in laboratory-engineered mutants. Further dissection of the WGS data can help elucidate potential genetic drivers of TR acquisition and add further knowledge as to whether the TR34/L98H and TR46/Y121F/T289A resistance genotypes derived from a single origin. This report adds another piece to the complex picture of emerging azole-resistant A. fumigatus and might serve to stimulate further research.

Dr. Hare is a molecular biologist at the Mycology Laboratory at Statens Serum Institut, Copenhagen, Denmark, where he completed his PhD on antifungal drug resistance in 2016. Besides antifungal resistance, his main research interests are molecular fungal diagnostics.

Top

Acknowledgment

We thank the entire Mycology Laboratory at Statens Serum Institut for their invaluable work in culturing, identification, and antimicrobial susceptibility testing. We acknowledge the staff responsible for the WGS workflow for their expedited service. We also thank laboratory technicians involved in PCR and DNA analyses, including Nissrine Abou-Chakra, for their invaluable aid and expertise in molecular biology.

Top

References

  1. Meis  JF, Chowdhary  A, Rhodes  JL, Fisher  MC, Verweij  PE. Clinical implications of globally emerging azole resistance in Aspergillus fumigatus. Philos Trans R Soc Lond B Biol Sci. 2016;371:20150460. DOIPubMedGoogle Scholar
  2. Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing. EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect. 2008;14:9824. DOIPubMedGoogle Scholar
  3. de Valk  HA, Meis  JF, Curfs  IM, Muehlethaler  K, Mouton  JW, Klaassen  CHW. Use of a novel panel of nine short tandem repeats for exact and high-resolution fingerprinting of Aspergillus fumigatus isolates. J Clin Microbiol. 2005;43:411220. DOIPubMedGoogle Scholar
  4. Ballard  E, Melchers  WJG, Zoll  J, Brown  AJP, Verweij  PE, Warris  A. In-host microevolution of Aspergillus fumigatus: A phenotypic and genotypic analysis. Fungal Genet Biol. 2018;113:113. DOIPubMedGoogle Scholar
  5. Sahl  JW, Lemmer  D, Travis  J, Schupp  JM, Gillece  JD, Aziz  M, et al. NASP: an accurate, rapid method for the identification of SNPs in WGS datasets that supports flexible input and output formats. Microb Genom. 2016;2:e000074.
  6. Delcher  AL, Salzberg  SL, Phillippy  AM. Using MUMmer to identify similar regions in large sequence sets. Curr Protoc Bioinformatics 2003;00:10.3.1–10.3.18.
  7. Price  MN, Dehal  PS, Arkin  AP. FastTree 2—approximately maximum-likelihood trees for large alignments. PLoS One. 2010;5:e9490. DOIPubMedGoogle Scholar
  8. Snelders  E, Camps  SMT, Karawajczyk  A, Schaftenaar  G, Kema  GHJ, van der Lee  HA, et al. Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS One. 2012;7:e31801. DOIPubMedGoogle Scholar
  9. Zhang  J, Snelders  E, Zwaan  BJ, Schoustra  SE, Meis  JF, van Dijk  K, et al. A novel environmental azole resistance mutation in Aspergillus fumigatus and a possible role of sexual reproduction in its emergence. MBio. 2017;8:e0079117. DOIPubMedGoogle Scholar
  10. Abdolrasouli  A, Rhodes  J, Beale  MA, Hagen  F, Rogers  TR, Chowdhary  A, et al. Genomic context of azole resistance mutations in Aspergillus fumigatus determined using whole-genome sequencing. MBio. 2015;6:e00536.PubMedGoogle Scholar
  11. Verweij  PE, Zhang  J, Debets  AJM, Meis  JF, van de Veerdonk  FL, Schoustra  SE, et al. In-host adaptation and acquired triazole resistance in Aspergillus fumigatus: a dilemma for clinical management. Lancet Infect Dis. 2016;16:e25160. DOIPubMedGoogle Scholar
  12. Snelders  E, Karawajczyk  A, Schaftenaar  G, Verweij  PE, Melchers  WJG. Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob Agents Chemother. 2010;54:242530. DOIPubMedGoogle Scholar
  13. Garcia-Rubio  R, Alcazar-Fuoli  L, Monteiro  MC, Monzon  S, Cuesta  I, Pelaez  T, et al. Insight into the significance of Aspergillus fumigatus cyp51A polymorphisms. Antimicrob Agents Chemother. 2018;62:e0024118. DOIPubMedGoogle Scholar
  14. Snelders  E, Camps  SMT, Karawajczyk  A, Rijs  AJMM, Zoll  J, Verweij  PE, et al. Genotype-phenotype complexity of the TR46/Y121F/T289A cyp51A azole resistance mechanism in Aspergillus fumigatus. Fungal Genet Biol. 2015;82:12935. DOIPubMedGoogle Scholar
  15. Gsaller  F, Hortschansky  P, Furukawa  T, Carr  PD, Rash  B, Capilla  J, et al. Sterol biosynthesis and azole tolerance is governed by the opposing actions of SrbA and the CCAAT binding complex. PLoS Pathog. 2016;12:e1005775. DOIPubMedGoogle Scholar

Top

Figures
Table

Top

Cite This Article

DOI: 10.3201/eid2503.180297

Original Publication Date: January 31, 2019

Table of Contents – Volume 25, Number 3—March 2019

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Maiken C. Arendrup, Statens Serum Institut, Building 43-317, Artillerivej 5, 2300, Copenhagen S, Denmark; ; Rasmus K. Hare, Statens Serum Institut, Building 43-315, Artillerivej 5, 2300, Copenhagen S, Denmark

Send To

10000 character(s) remaining.

Top

Page created: February 19, 2019
Page updated: February 19, 2019
Page reviewed: February 19, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external